Director Jason Raleigh Nunn of Addex Therapeutics Ltd. filed a Form 4 on November 13, 2026, disclosing the acquisition of 942,854 stock options on November 11, 2026, with an exercise price of $0.026 per share.
Key Highlights
- Reporting person: Jason Raleigh Nunn, identified as a Director of Addex Therapeutics Ltd. (NASDAQ:ADXN)
- Transaction date: November 11, 2026, with the form filed November 13, 2026
- Securities acquired: 942,854 stock options (right to buy), transaction code A
- Exercise price: $0.026 per share, converted from CHF to USD at an exchange rate of $1.1995 per CHF 1.00 as of November 11, 2026
- Vesting schedule: Equal monthly installments over a 4-year period beginning at the exercisable date of November 11, 2026
- Expiration date: November 10, 2036
- Total derivative securities owned following transaction: 992,854, held directly
Nunn Option Grant Details: Addex Therapeutics November 2026
According to the filing, Jason Raleigh Nunn, a director of Addex Therapeutics Ltd., acquired 942,854 stock options on November 11, 2026, through a transaction coded "A" (acquired). The filing reports a price of $0 for the derivative security itself, while the exercise price of $0.026 per share reflects a conversion from Swiss francs to U.S. dollars at the rate of $1.1995 per CHF 1.00 as of the transaction date. Each stock option grants the right to purchase one ADXN share listed on the SIX Swiss Exchange, as stated in the filing's explanatory notes.
The filing discloses that the granted options vest in equal monthly installments over a 4-year period beginning at the exercisable date of November 11, 2026, and are set to expire on November 10, 2036. Following this transaction, the filing reports that Nunn beneficially owns 992,854 derivative securities in total, held directly. The filing does not report any transactions in Table I covering non-derivative (common stock) holdings.
The Form 4 was signed by Lenaic Nathanael Teyssedou by power of attorney on November 13, 2026. The filing identifies Nunn's address as Chemin des Mines 9, Geneva, Switzerland. The foreign trading symbol listed is ADXN, referencing Addex Therapeutics Ltd.'s listing on the SIX Swiss Exchange.
What Was Disclosed
Addex Therapeutics director Jason Raleigh Nunn reported the acquisition of 942,854 stock options at an exercise price of $0.026 per share, vesting monthly over four years, with a total post-transaction beneficial ownership of 992,854 derivative securities, held directly.




Please wait processing your request...